原发性免疫性血小板减少症停用TPO受体激动剂后的持续缓解:一项前瞻性多中心研究
该前瞻性多中心干预研究纳入48例持续或慢性原发性免疫性血小板减少症且对TPO受体激动剂达完全缓解的成人,主要终点为第24周无其他ITP特异性药物下达到持续缓解(血小板>30×10^9/L且无出血)的比例,48例中27例达到;第52周48例中25例达到。单细胞RNA测序显示无持续缓解者CD8+ T细胞NF-κB信号通路富集,基线CD69过表达。
要点
- 第24周48例中27例达到持续缓解,第52周48例中25例达到。
- 第24周48例中15例达到持续完全缓解,第52周48例中14例达到。
- 复发患者无严重出血事件,再次使用TPO受体激动剂12例中11例达完全缓解。
核心结论
- 结果强烈支持对治疗中达稳定完全缓解的慢性ITP患者采用逐步减量并停用TPO受体激动剂的策略。
研究设计与样本
- 前瞻性多中心干预研究,纳入48例持续或慢性原发性ITP且对TPO受体激动剂达完全缓解的成人,中位年龄58.5岁,48例中30例在启动TPO受体激动剂时为慢性ITP。
主要发现
- 意向治疗分析中,第24周48例中27例达到持续缓解,48例中15例达到持续完全缓解;第52周48例中25例达到持续缓解,48例中14例达到持续完全缓解。
- 复发患者中未发生严重出血事件。
- 再次接受TPO受体激动剂治疗的患者中,12例中11例达到完全缓解。
- 第24周持续缓解未发现显著临床预测因素。
- 单细胞RNA测序显示,停用TPO受体激动剂后无持续缓解的患者CD8+ T细胞中肿瘤坏死因子α经NF-κB信号通路特征富集,且这些患者基线CD8+ T细胞CD69显著过表达,与达到持续完全缓解/持续缓解者相比。
关键数值与推荐
- 持续缓解定义为血小板计数>30×10^9/L且无出血,且未使用其他ITP特异性药物。
- 持续完全缓解定义为血小板计数>100×10^9/L且无出血。
临床怎么用
- 作者认为结果强烈支持对治疗中达稳定完全缓解的慢性ITP患者采用逐步减量并停用TPO受体激动剂的策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sustained response off treatment (SROT) after thrombopoietin receptor agonist (TPO-RA) discontinuation has been reported in immune thrombocytopenia (ITP). This prospective multicenter interventional study enrolled adults with persistent or chronic primary ITP and complete response (CR) on TPO-RAs. The primary end point was the proportion of patients achieving SROT (platelet count >30 × 109/L and no bleeding) at week 24 (W24) with no other ITP-specific medications. Secondary end points included the proportion of sustained CR off-treatment (SCROT, platelet count >100 × 109/L and no bleeding) and SROT at W52, bleeding events, and pattern of response to a new course of TPO-RAs. We included 48 patients with a median age of 58.5 years; 30 of 48 had chronic ITP at TPO-RA initiation. In the intention-to-treat analysis, 27 of 48 achieved SROT, 15 of 48 achieved SCROT at W24; 25 of 48 achieved SROT, and 14 of 48 achieved SCROT at W52. No severe bleeding episode occurred in patients who relapsed. Among patients rechallenged with TPO-RA, 11 of 12 achieved CR. We found no significant clinical predictors of SROT at W24. Single-cell RNA sequencing revealed enrichment of a tumor necrosis factor α signaling via NF-κB signature in CD8+ T cells of patients with no sustained response after TPO-RA discontinuation, which was further confirmed by a significant overexpression of CD69 on CD8+ T cells at baseline in these patients as compared with those achieving SCROT/SROT. Our results strongly support a strategy based on progressive tapering and discontinuation of TPO-RAs for patients with chronic ITP who achieved a stable CR on treatment. This trial was registered at www.clinicaltrials.gov as #NCT03119974.
引用
- Guillet S, Crickx E, Azzaoui I, et al. Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study. Blood. 2023. PMID: 36893453. doi:10.1182/blood.2022018665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。